MEMS Microfluidic Biosensor Industrialisation Director — Point-of-Care Diagnostics

The mandate

A MEMS biosensor produces strong analytical sensitivity in hand-built cartridges, but pilot assemblies show bubble trapping, inconsistent wetting, surface fouling and baseline drift across reagent lots. Sensor, assay and plastics teams optimise separate controls, while the reader algorithm compensates for signals the factory cannot reproduce. The defined problem is to establish a manufacturable sensor-cartridge system with diagnostic evidence tied to real assembly and sample variability.

The deliverables are a sensor-to-result failure model, device and cartridge genealogy, fluidic tolerance stack, surface and reagent control plan, calibration architecture, production-test concept, pilot build, reliability matrix, transfer dossier and residual diagnostic limitations. Outputs must connect flow, sensing and algorithm behaviour without using software correction to hide an unstable physical path. Each critical parameter needs a measurement method and accountable owner.

Four milestones govern five months: use-case and failure-mechanism baseline by 30 October 2026; approved fluidic, surface and calibration control design by 11 December; witnessed pilot build plus environmental and sample-matrix testing by 29 January 2027; and accepted transfer dossier, service recovery and client-team rerun by 26 February. Milestones use production-intent cartridges and declared reagent and sample lots.

Acceptance requires MEMS engineers to reproduce sensor distributions, cartridge manufacturing to hold fluidic tolerances, assay teams to demonstrate representative matrix performance and quality to trace every critical control. The sponsor returns one consolidated defect register within six working days. Passing processed outputs cannot close acceptance when bubbles, wetting history, fouling or calibration state is missing from the underlying evidence.

The client provides sensor wafers, cartridge designs, surface processes, reagents, reader electronics, raw traces, sample protocols, manufacturing access, quality requirements and approved biological materials. It funds pilot tooling and declares biosafety and diagnostic-use boundaries. The director cannot approve clinical claims, release product, change specimen consent or select commercial manufacturers beyond the accepted scope.

Why this is external work

The failure crosses silicon, fluids, surfaces, biology, plastics and signal processing, so every internal function can show a locally reasonable result. A neutral industrialisation director can hold the integrated diagnostic outcome without privileging an assay or algorithm workaround. The assignment ends when the client reproduces a controlled pilot build and accepts explicit limits for further validation.

What you will own

• Connect MEMS device variation, surface state, fluid path, reagent lot, sample matrix, reader and algorithm to result quality.
• Quantify bubble formation, wetting, dead volume, flow resistance, evaporation and fouling across manufacturing and use conditions.
• Establish genealogy for wafers, dice, coatings, cartridges, adhesives, reagents, assembly equipment and calibration files.
• Design factory tests that predict fluidic and sensing performance without consuming impractical biological material or full assays.
• Govern pilot builds across tolerance corners, environmental exposure, shipping, storage, operator handling and realistic sample matrices.
• Separate appropriate calibration from correction that conceals physical instability or creates unmonitored diagnostic bias.
• Deliver the accepted transfer dossier, production controls, residual limitations, service procedures and client-led reproduction.

Candidate qualifications

• Directed MEMS biosensor or microfluidic diagnostic industrialisation from laboratory assemblies into traceable production-intent cartridges at commercial scale.
• Can evidence an assay or algorithm success invalidated by fluidic, surface, reagent or manufacturing variability.
• Understands MEMS sensing, microfluidics, wetting, biofouling, surface chemistry, calibration and production-test constraints.
• Has governed statistically credible pilot builds using biological matrices within quality, biosafety and design-control boundaries.
• Integrated silicon, plastics, assay, electronics, software and contract-manufacturing teams through traceable physical evidence.
• Converts research sensitivity into manufacturable diagnostic performance without making unsupported clinical claims.

Non-negotiables

• Will attend all Basel, Lausanne and Dublin sensor, cartridge and manufacturing sessions.
• Has personally transferred MEMS or microfluidic hardware using production-intent biological sample evidence.
• Accepts milestone rejection when processed results cannot be traced to physical, reagent and calibration state.
• Will disclose MEMS fab, cartridge, assay, diagnostic and contract-manufacturing relationships before engagement.

1. 49 words maximum. Which microfluidic effect most undermined an otherwise strong biosensor or assay result?
2. 49 words maximum. How would you distinguish necessary calibration from concealment of unstable physical behaviour?
3. 49 words maximum. What factory test best predicts sensor-cartridge performance without running a complete assay?